• Creatore Discussione laz
  • Data di inizio
  • Due nuove obbligazioni Societe Generale, in Euro e in Dollaro USA

    Societe Generale porta sul segmento Bond-X (EuroTLX) di Borsa Italiana due obbligazioni, una in EUR e una in USD, a tasso fisso decrescente con durata massima di 15 anni e possibilità di rimborso anticipato annuale a discrezione dell’Emittente.

    Per continuare a leggere visita questo LINK
Direi che il mercato ha accolto bene la notizia... ;)

Ieri evidentemente finta al ribasso per raccoglierne un po'...

E oggi...


  • tgen.jpg
    14,2 KB · Visite: 111
La nwes è molto + importante di quanto sembri
Sembra, sembra... ;)

Il trend resta formente al rialzo...
Ecco il perché...

Targeted Genetics files to sell 16.3 mln shares
Thursday June 17, 5:47 pm ET

WASHINGTON, June 17 (Reuters) - Gene therapy company Targeted Genetics Corp. (NasdaqSC:TGEN - News) filed on Thursday with the U.S. Securities and Exchange Commission to periodically sell up to 16.3 million shares of common stock.
The Seattle, Washington-based company said in a registration statement that it plans to use the proceeds, $24.6 million based on Thursday's closing stock price of $1.51, for working capital and other general corporate purposes, including acquisitions.

Under a shelf registration, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale.
Targeted Genetics Named One of Washington State's Fastest Growing Technology Companies in Deloitte Technology Fast 50 Program
SEATTLE, Oct. 1 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation [TGEN] has been named to Deloitte's Technology Fast 50 Program for Washington State, a ranking of the 50 fastest growing technology companies in the area by Deloitte & Touche LLP. Rankings are based on the percentage of growth in fiscal year revenues over five years, from 1999-2003. The award was presented last evening in Seattle.

"Targeted Genetics' commitment to product commercialization supports the Company's growth and success over the last several years. We are pleased that this progress has resulted in a fourth Deloitte & Touche Fast 50 award during the past five years," said H. Stewart Parker, president and chief executive officer of Targeted Genetics. "We continue to maintain our leadership position in the field of gene delivery with ongoing clinical programs targeting the treatment of cystic fibrosis and rheumatoid arthritis and the prevention of AIDS."

The 2004 Washington State Technology Fast 50 list was developed by Deloitte & Touche based on an analysis of revenue growth from 1999 to 2003. Growth percentages were calculated and compared among technology companies in Washington State that met the Fast 50 eligibility criteria. Winners of the 19 regional Technology Fast 50 programs in the United States and Canada are automatically entered in the Deloitte Technology Fast 500 program, which ranks North America's top 500 fastest growing technology companies. For more information on the Fast 50 or Fast 500 programs, visit

Targeted Genetics develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies. For more information about the Company visit its website at

NOTE: This release contains forward-looking statements regarding our projected financial resources, intellectual property, clinical trials and regulatory filings and anticipated data from our clinical and preclinical programs. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including failure of our partners to provide funding, our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain or maintain regulatory approvals, our failure to maintain or protect our intellectual property and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectation.

Targeted Genetics Corporation
CONTACT: Courtney Self of Targeted Genetics Corporation,

Web site:

Web site:


  • tgen2.PNG
    30 KB · Visite: 224
Oggi ho approfittato del panic sell per metterne un po' in portafoglio,non si sa mai che mi dia un po' di soddisfazione per fine anno.Vedremo........
Occhio :) è ancora sottomessa ma sta scivolando border line, una accellerazione muterebbe il corso, da tenere in wacth
Da oggi ci sono anche io.
Mi sembra pronta al decollo.
Ma che bello vederti anche qui, Magia! Io ci sono da prima dell'estate.

Su Yahoo leggo che se rompe con volumi 1,35... potrebbe arrivare sparata a 1,85...

Avanti insieme!

laz ha scritto:
Ma che bello vederti anche qui, Magia! Io ci sono da prima dell'estate.

Su Yahoo leggo che se rompe con volumi 1,35... potrebbe arrivare sparata a 1,85...

Avanti insieme!


guarda il chart è ancora attuale è sopra la ribassita
  • Like
Reazioni: laz


  • tgen.jpg
    41,7 KB · Visite: 140
Speriamo sia la volta buona...

...ho tutto in essa...da un anno...gooooooooooo tgen...goooooooooooooo...
  • Like
Reazioni: laz
Close 1,4 con volumi... di meglio non potevamo chiedere... ;)


Ongoing Phase I Clinical Trial

Targeted Genetics, in collaboration with the International AIDS Vaccine Initiative, is currently conducting a Phase I clinical trial of tgAAC09 as a single-shot vaccine. tgAAC09 uses Targeted Genetics AAV technology to elicit immune system responses in an effort to protect against AIDS. tgAAC09 is designed to elicit both an antibody and a cell-mediated immune response. The Phase I, dose-escalation clinical trial is a double-blind, placebo-controlled study enrolling up to 50 volunteers, both men and women, who are uninfected with HIV and in good general health. Each volunteer receives a single intramuscular injection into the upper arm. Following vaccination, study participants will be monitored for safety and evaluated to see if tgAAC09 can elicit an immune response.

This trial began in the fourth quarter of 2003 and includes participating clinical trial sites in Belgium and Germany. Targeted Genetics expects to complete the dose-escalation portion of this clinical trial by the end of 2004.

Completed Preclinical Studies

Targeted Genetics has completed a number of preclinical studies designed to assess the safety, tolerability and potential dosing of tgAAC09. These preclinical studies demonstrate that tgAAC09 was well tolerated at all dose levels evaluated and that there were no dose-dependent clinically significant adverse events. Studies of tgAAC09 in animal models also demonstrate that the vaccine is expressed in muscle tissue and induces both B-cell and T-cell responses.

Highlighted preclinical results include:

No dose-related or clinically significant safety issues;

Vaccine did not integrate into host chromosome;

Robust and sustained dose-dependent antibody and antigen-specific T cell responses; and

Vaccinated animals were protected from disease with statistically significant reduced viral load at peak and set-point.